Value

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

By

What's holding back value-based pricing deals from moving beyond the pilot phase?

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Five things for pharma marketers to know: Tuesday, May 30, 2017

Five things for pharma marketers to know: Tuesday, May 30, 2017

By

Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

By

Execs stressed the importance of collaboration, consumer-mindedness.

Five things for pharma marketers to know: Thursday, April 27, 2017

Five things for pharma marketers to know: Thursday, April 27, 2017

By

Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

By

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

By

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Five things for pharma marketers to know: Tuesday, June 7, 2016

Five things for pharma marketers to know: Tuesday, June 7, 2016

By

Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.